Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Tolerability of LY4268989 (MORF-057) in Healthy Participants
NCT07707375Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1 trial of LY4268989 in inflammatory bowel disease (IBD) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration and Area Under the Concentration Curve. Started Jul 2026; status: active, not recruiting.
02
Drugs
LY4268989
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07707375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707375.